PERSON
Athira Pharma’s Stock Plummets Following Disappointing Alzheimer’s Drug Trial Results
Athira Pharma, Alzheimer’s disease, fosgonimeton, LIFT-AD study, stock crash
FDA Authorizes Novavax’s Updated COVID-19 Vaccine for Emergency Use
Novavax COVID-19 Vaccine, FDA Authorization, Emergency Use, Protein-Based Vaccine, JN.1 Variant
George Medicines Unveils Promising Low-Dose Triple Combination Pill for Hypertension Management
Hypertension, Triple Combination Pill, Low-Dose, Blood Pressure Control, GMRx2, George Medicines
Novavax’s Updated COVID-19 Vaccine Receives FDA Emergency Use Authorization
Novavax, COVID-19 vaccine, FDA, Emergency Use Authorization, protein-based vaccine, JN.1 variant
Arrowhead Pharmaceuticals Highlights Key Pancreatitis Data from Phase 3 Lipid Disease Study to Distinguish Itself from Ionis
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Plozasiran, Olezarsen, Severe Hypertriglyceridemia (SHTG), Familial Chylomicronemia Syndrome (FCS), Acute Pancreatitis, RNAi Therapy, Triglyceride Reduction
Neurocrine Biosciences Advances Schizophrenia Treatment with Positive Phase 2 Data for NBI-1117568
Neurocrine Biosciences, schizophrenia, NBI-1117568, Phase 2 data, Phase 3 advancement, muscarinic M4 selective acetylcholine receptor agonist
UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development
UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
Eli Lilly Launches Direct-to-Consumer Sales of Zepbound for Weight Loss
Eli Lilly, Zepbound, weight loss medication, direct-to-consumer sales, affordable pricing, obesity treatment
Tome Biosciences Halts Operations Amid Financial Strains, CEO Focuses on Strategic Deals
Tome Biosciences, gene editing, layoffs, financial struggles, strategic options, Rahul Kakkar